Autotelic Bio Co.
Latest round
- Series B
Last raised
- Mar 2022
Total raised
- $19M
Investors
- 16
About Autotelic Bio Co.
, Ltd., Ltd. focuses on creating advanced cancer treatments and was founded in 2015 in Cheongju, South Korea., Ltd. is dedicated to developing cutting-edge cancer therapies, prominently featuring its proprietary Anti-Sense Oligonucleotide (ASO) drugs and small molecule compounds. These ASO drugs utilize advanced informatics platforms, such as ASODE+ and CATs, to inhibit disease-related proteins. The firm is actively researching three ASO cancer treatments and two small molecule therapies, including ATB-101 for hypertension and diabetes, and ATB-301 targeting TGF-ß2 in cancer., Ltd. generates revenue through partnerships with healthcare institutions and pharmaceutical companies. The company sells its ASO and small molecule therapies directly to hospitals and clinics, along with potential licensing agreements with larger firms., Ltd.S. and European markets. With a commitment to advancing its therapeutic offerings, Autotelic Bio seeks to address the evolving demands in the pharmaceutical landscape.
Who invested in Autotelic Bio Co.
16 investors across 4 rounds
See all investors in Autotelic Bio Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Autotelic Bio Co.
Who invested in Autotelic Bio Co.?
Autotelic Bio Co. has 16 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Autotelic Bio Co. raised?
Autotelic Bio Co. has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Autotelic Bio Co. last raise money?
Autotelic Bio Co.'s most recent round on record is a Series B, in Mar 2022.
What does Autotelic Bio Co. do?
Autotelic Bio Co. is a biotechnology company.
Where is Autotelic Bio Co. headquartered?
Autotelic Bio Co. is headquartered in Cheongju, South Korea.
Which VCs invest in companies like Autotelic Bio Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Autotelic Bio Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Autotelic Bio Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.